Prescription Drug Injuries

Published on: March 25, 2025

Ozempic and Wegovy Linked to Vision Loss

medical-5835701_640-e1741657233713 Semaglutide in the form of drugs like Ozempic, Mounjaro, Wegovy, Rybelsus and Zepbound may increase the risks of vision loss. These drugs are taken to manage type 2 diabetes and obesity and have the potential to help other medical problems like depression, addiction, and Alzheimer’s. Unfortunately, it also appears that one of the drugs’ potential side effects is a rare kind of vision loss, non-arteritic anterior ischemic optic neuropathy (NAION). Around 12% of people around the country has taken semaglutide drugs and around 6% of Americans are currently taking them. No direct causal link has been established, but as popularity of these drugs grow, it’s important to be aware of this possible risk. If you suffered NAION while on Ozempic, Wegovy or another GLP-1 drug, you should call the seasoned Chicago-based dangerous pharmaceuticals lawyers of Moll Law Group.

Call Moll Law Group About Your Semaglutide Claim

Only a small group of patients taking semaglutide have experienced vision issues. A JAMA study, one of several studies, looked at 9 patients that had vision trouble while taking semaglutide.

NAION is a non-inflammatory disease in which the blood supply to the optic nerve is harmed and the patient suffers a sudden partial vision loss that’s permanent. The study was initiated because a patient experienced a painless vision loss while on the drug but had the issue resolve favorably when semaglutide was stopped; when he went back on, he had the same problem with the other eye. The researcher looked into whether other neuro-ophthalmologists had seen this in their patients and found nine cases that are featured in his study. Seven out of nine of the patients, all of them in their 50s and 60s, had typical presentations of NAION, which usually affects only one eye at once, but some had unusual symptoms. Researchers are trying to figure out whether being on semaglutide actually causes NAION and other vision loss.

Continue reading →

Published on: February 25, 2025

Depo-Provera Claims Now Centralized and Part of Multidistrict Litigation

By Moll Law Group

injection-957260_640-e1739547652876 In an important legal step, the Depo-Provera birth control lawsuits have been centralized and transferred to multidistrict litigation that will take place in Florida. There were 27 lawsuits pending in 8 districts, and another 41 related actions pending in 15 districts. Plaintiffs had proposed to centralize the litigation in the Northern District of California or the Central District of California. However, the Panel on Multidistrict Litigation elected to move the cases to Florida. If you were harmed by Depo-Provera, you may have grounds to pursue damages in a product liability lawsuit. The seasoned Chicago-based lawyers of Moll Law Group represent plaintiffs around the country. Billions have been recovered in product liability lawsuits with which we’ve been involved.

Call Moll Law Group About the Harm You’ve Suffered from Depo-Provera

The plaintiffs who brought Depo-Provera lawsuits have alleged that they used the injectable contraceptive. Studies now show that long-term use of Depo-Provera can result in an increased risk of developing meningiomas (types of brain tumor) and the plaintiffs argued that they developed intracranial meningioma that was caused by use of Depo-Provera or a generic version of it. They sought centralization of these claims because they have substantially similar misrepresentation and product liability claims.

The Judicial Panel on Multidistrict Litigation found that the actions that were brought before them involve common questions of fact and that centralizing these cases in the Northern District of Florida will serve the parties’ convenience, as well as the witnesses, and promote the just and efficient conduct of the litigation.

Continue reading →

Published on: October 22, 2024

Brain Tumors Linked to Depo-Provera

By Moll Law Group

injection-4544448_640 The drug company Pfizer manufactures the popular form of contraception Depo-Provera. It’s a contraceptive administered via an injection every three months; it suppresses ovulation and thickens cervical mucus to block sperm’s ability to get to the egg. However, studies have shown that there is a link between increased risk of brain tumors and Depo Provera, and this has resulted in an increased uptick in danger drug lawsuits filed. If you were harmed by Depo-Provera, you should call the seasoned Chicago-based product liability lawyers of Moll Law Group. Billions have been recovered in cases with which we’ve been involved.

Consult Attorneys at Moll Law Group

Many patients use hormonal birth control. One of these methods is Depo-Provera, an intramuscular injection of medroxyprogesterone acetate, a synthetic form of progesterone, into a buttock or arm. It impacts reproduction. The chances of getting pregnant are reduced through the alteration of the uterine lining and stop of ovulation. It’s more than 99% effective if it’s routinely given on schedule.

Depo-Provera has been connected to a patient’s increased risk of meningioma, which is a kind of brain tumor. In fact, studies have revealed that long-term use of Depo-Provera markedly ups the chances of developing these kinds of tumors. Specifically, the British Medical Journal has indicated a 5.6-fold increase in risk of intracranial tumors due to Depo-Provera—which can cause brain pressure that requires invasive surgery that carries severe health problems and complications. You may be especially vulnerable if you’ve used Depo-Provera for a lengthy time. The symptoms of meningioma you should look out for include hearing loss, seizures, vision problems, persistent headaches, and weakness. It’s noteworthy that other progestogens like levonorgestrel intrauterine systems and dydrogesterone don’t seem associated with an increased risk.

Continue reading →

Published on: July 16, 2024

Manufacturer Recall of Potassium Chloride Extended-Release Capsules

By Moll Law Group

man-1846050_640-e1721085626928 Recently, Glenmark Pharmaceuticals recalled 114 batches of 750 mg. potassium chloride extended-release capsules USP 10 mEq because of dissolution failure. The failed dissolution of these capsules can result in high potassium levels, a condition called hyperkalemia. This can lead to a patient’s cardiac arrest. Normal potassium levels are essential to your body; potassium assists with the functioning of kidneys, heart, muscles, nerves, and cells. If you were harmed by any of the recalled potassium chloride extended release capsules, consult the seasoned Chicago-based dangerous drug attorneys of Moll Law Group about your legal options.

Give Our Lawyers A Call

As a patient, you may need to take potassium chloride extended release capsules orally, especially if you have an underlying medical condition that changes how potassium is excreted. Such underlying conditions include heart failure, renal dysfunction or hypertension. Each of these make it reasonably probable that you would develop hyperkalemia and cause severe adverse events. While it’s possible you might be asymptomatic, there is a chance you would suffer serious muscle weakness, cardiac arrhythmia, or even death.

The recalled capsules had been distributed around the country to wholesalers, distributors, and retail stores in 100-count and 500-count bottles. The manufacturer hasn’t yet gotten reports of hyperkalemia, or a serious adverse event related to the capsules. are packaged in 100-count (NDC 68462-357-01) and 500-count (NDC 68462-357-05) bottles.

Continue reading →

Published on: July 9, 2024

Settlement of Valsartan Lawsuit Nears for Some

By Moll Law Group

blood-pressure-monitor-1749577_640-e1720474938721 Plaintiffs sued Hetero, the manufacturer of valsartan, a generic blood pressure medication, because it was contaminated with carcinogens, and they alleged it caused cancer. The lawsuits were consolidated in 2019. These cases are coming closer to settlement. Recently, the United States District Judge Renée M. Bumb who is presiding over the multidistrict litigation ordered both sides to finalize a settlement agreement in all of the plaintiff groups; there are three groups, one for personal injury, another for economic loss, and still another for medical monitoring. The deadline was June 30. If you were harmed by Valsartan, you should call the seasoned Chicago-based lawyers of Moll Law Group. Billions have been recovered in cases with which we’ve been involved.

Contact Moll Law Group About Your Valsartan Cancer Claim

Valsartan, manufactured safely by Novartis Pharmaceuticals Corp. under the brand name Diovan, functions by relaxing a patient’s blood vessels. This improves flow and reduces pressure. When the patent expired, various generic manufacturers in China and India began selling the drug, which they made with a different manufacturing process. The U.S. Food and Drug Administration investigated claims that drugs manufactured overseas contained NDMA or N-nitrosodimethylamine or NDEA (N-nitrosodimethylamine).

In 2018, the generic Valsartan was recalled around the world because of its unacceptable levels of carcinogenic toxins. Many patients, including around 3 million Americans, had not known they were taking contaminated drugs that could seriously harm them.

Continue reading →

Published on: December 12, 2023

Supreme Court Heard Arguments to Challenge OxyContin Settlement

By Moll Law Group

headache-1540220_640-e1702313969782 The Supreme Court heard arguments related to a challenge to the bankruptcy deal that’s intended to compensate victims of highly addictive pain killer OxyContin. Based on the questions judges asked, court watchers believe the Court is split. The manufacturer of Oxycontin, Purdue Pharma, entered into a deal to pay billions to people harmed by the opioids they made and sold. That deal protected members of the Sackler family from personal liability. If you were injured by Oxycontin or another highly addictive pain killer, you should call the seasoned Chicago-based dangerous drug lawyers of Moll Law Group. Billions have been recovered in product liability lawsuits with which we’ve been involved.

Contact Moll Law Group About Your Claim

The case that the Court is hearing arose from complex circumstances. The Sackler family took assets from the manufacturer of Oxycontin, Purdue Pharm and shifted those assets overseas, which then triggered the problem that the company no longer has enough money to pay its creditors, such as those injured by pain killer. Purdue Pharma pled guilty to three criminal charges by 2020. It agreed that it owed $8 billion in criminal and civil fines to state and local governments trying to address the opioid crisis.

Based on this, the company reached a deal in bankruptcy court that would reimburse victims of the epidemic along with the harmed by an amount less than it might have paid, had it not shifted its assets overseas.

Continue reading →

Published on: April 6, 2020

The Food and Drug Administration Pulls Zantac from Pharmacy Shelves

By Moll Law Group

FDA Recall Earlier this week, the U.S. Food and Drug Administration issued a news release requesting manufacturers to withdraw all products containing the popular heartburn drug, ranitidine, the active ingredient in the medication, Zantac. The order applies to both prescription and over-the-counter medications. In light of the ongoing COVID-19 national emergency, those who have medicine containing ranitidine on hand are being asked not to return the product to the pharmacy, as is typically recommended. Instead, the FDA is recommending the medication be destroyed according to the disposal suggestion contained in the medication guide or package insert. All formulations of ranitidine are impacted, including pills, injections, and compounded medications that include ranitidine.

The recent recall is the latest step in an escalating investigation surrounding a contaminant known as N-Nitrosodimethylamine (NDMA), which is commonly found in ranitidine. Through its research, the FDA found that the impurities in some ranitidine products increase over time when stored at higher temperatures, potentially resulting in dangerous levels of NDMA.

In its official statement, the FDA explained that it didn’t see unacceptable levels of NDMA in the many samples they tested. Nevertheless, since they did not know how or for how long the product might have been stored they decided that it should not be available to consumers and patients unless its quality could be assured.

Continue reading →

Published on: October 21, 2016

Moll Law Group Files Personal Injury Case Against Major Drug Manufacturer

By Moll Law Group

Earlier this year, a study was released showing that certain heartburn medications – known as proton-pump inhibitors – can cause irreversible damage to those who take the medication. The study was released by a respected medical journal and evaluated a group of about 250,000 patients. The group of medications known as proton-pump inhibitors includes the popular medications Nexium, Prilosec, and Prevacid.

According to a news report released earlier this year, those who have taken these medications have a 20-50% chance of developing chronic kidney disease. However, there are almost 13 million Americans who are prescribed proton-pump inhibitors. It is estimated that up to 70% of these patients are inappropriately prescribed the medication, and many long-term users could cease using the medication. The study found that those users who took the medication twice a day had a 46% chance of developing kidney-related ailments, while users who took the medication only once a day had only a 15% chance of developing side effects.

The harmful effects of taking proton-pump inhibitors most notably include chronic kidney damage, which can result in the body’s inability to effectively filter blood. This can lead to nephritis, the need for regular dialysis, and even the need for a kidney replacement. In addition, patients may suffer from heart problems, obesity, and high blood pressure.

Continue reading →

Published on: October 13, 2016

Pharmacists Required to Preserve Evidence for Dispensing Error Cases

By Moll Law Group

Recently, a man was prescribed Valsartan, a medication used to treat high blood pressure, and the pharmacy mistakenly gave the man a container with both Valsartan pills and Lithium pills. The pills were the same color but different shapes. The man took the medication as prescribed. When the man’s wife discovered the mistake a few days later and brought back the container, a pharmacist confirmed that the container had both pills inside. The pharmacy then set aside the medication and later destroyed it, in accordance with the company’s policy.

Soon afterward, the man experienced numbness and weakness in his hand and checked into the hospital. The treating physician believed that the man had a reaction to the Lithium pills he mistakenly took. The man’s symptoms continued to worsen in the following months, and he was diagnosed with carpal tunnel syndrome and polyneuropathy, allegedly due to his consumption of Lithium. The man had surgery performed on his hand and arm, but he continued to suffer from pain and stiffness in his hand.

The man filed a negligence case against the pharmacy for his injuries. During discovery, the pharmacy was asked to turn over the container with the mixed pills to determine if some of the pills were Lithium pills. The pharmacy stated that it had destroyed the container and its contents, pursuant to the store’s policy. Due to the pharmacy’s destruction of evidence, the man filed for sanctions against the pharmacy.

Continue reading →

Published on: March 12, 2016

FDA Warns Women of Potential Risks of Essure

By Moll Law Group

The U.S. Food and Drug Administration (FDA) recently announced that it would take actions to provide women with information about the risks of using Essure, a form of permanent birth control. This form of birth control involves inserting flexible coils through the cervix and vagina into the fallopian tubes. After about three months, scar tissue forms around the coils and makes a barrier in order to prevent conception.

The FDA recognized that there are potential complications related to these types of implantable forms of sterilization and that it should take actions in order to address these risks. These actions include requiring a clinical study to assess the risks and requiring warnings on the product labels. The FDA stated that the actions recognize that “more rigorous research is needed to better understand if certain women are at heightened risk of complications.”

The FDA, an agency within the U.S. Department of Health and Human Services, protects public health by ensuring that food and drugs are safe for people to use. The FDA’s position is that while Essure is safe for most women, some women may be at risk for complications. Those complications may include pain, tears, bleeding, and allergic reactions.

Continue reading →